Related Experiment Video
Updated: Apr 21, 2026
Author Spotlight: Developing Parmodulins to Target Protease-Activated Receptors for Inflammation Control
Published on: May 24, 2024
Probing PARP1-inhibitor complexes for the development of novel inhibitors
1Maulana Azad National Institute of Technology (MANIT) Department of Mathematics Madhya Pradesh India.
Abstract:
Poly (ADP-ribose) polymerase 1 (PARP1) is the most important member of the PARP family which has been shown to have a direct involvement in the development of cancer. A strategy to rationalize the structure based drug discovery of PARP1 inhibitors has been discussed. So far studies regarding varied scaffold PARP1 inhibitors have been done, however the current study focus on how the available data from potent PARP1 inhibitors could be combined and utilized for developing a robust model for the development of novel inhibitors. Through detailed analyses of PARP1-inhibitor binding, a pharmacophore model has been developed followed by a virtual screen of potential inhibitors. The resulting high-affinity binding hits following the defined pharmacophore model and making the critical interactions were selected as final potential leads. Hence, using the approaches of pharmacophore design, docking based virtual screening and conformation alignment, we have identified important leads which satisfy all parameters of the screening process. The developed pharmacophore model as well as the strategy is very straightforward for screening novel inhibitors and could thus be used as a prototype for PARP1 structure based drug discovery.
Insights
Researchers developed a new pharmacophore model and virtual screening strategy to discover novel Poly (ADP-ribose) polymerase 1 (PARP1) inhibitors for cancer drug discovery. This approach identifies high-affinity compounds for structure-based drug design.
Area of Science:
- Oncology
- Medicinal Chemistry
- Computational Biology
Background:
- Poly (ADP-ribose) polymerase 1 (PARP1) is crucial in cancer development.
- Structure-based drug discovery of PARP1 inhibitors is a key strategy.
- Existing studies explore various PARP1 inhibitor scaffolds.
Purpose of the Study:
- To develop a robust model for novel PARP1 inhibitor discovery by integrating data from existing potent inhibitors.
- To utilize pharmacophore modeling and virtual screening for identifying promising drug candidates.
- To establish a prototype strategy for PARP1 structure-based drug discovery.
Main Methods:
- Detailed analysis of PARP1-inhibitor binding interactions.
- Development of a pharmacophore model based on binding data.
- Virtual screening of potential inhibitors against the pharmacophore model.
- Docking-based virtual screening and conformation alignment.
Main Results:
- Identification of high-affinity binding hits that satisfy the pharmacophore model.
- Selection of potential lead compounds making critical interactions with PARP1.
- Successful identification of novel inhibitors through the integrated screening process.
Conclusions:
- The developed pharmacophore model and strategy are effective for screening novel PARP1 inhibitors.
- This approach provides a straightforward method for structure-based drug discovery of PARP1 inhibitors.
- The strategy can serve as a prototype for future PARP1 inhibitor development.
More Related Videos
10:33Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
Published on: October 26, 2015
15:53Cell Death Associated with Abnormal Mitosis Observed by Confocal Imaging in Live Cancer Cells
Published on: August 21, 2013
